LDLR and Hepatic fibrosis: This could either mean that these subjects had already been identified as having a higher CV risk and were therefore on appropriate treatment or that liver fibrosis might reduce statin effectiveness by impairing LDL-receptor activity, thus hindering the clearance of atherogenic lipoproteins despite statin treatment.